PMID- 12794524
OWN - NLM
STAT- MEDLINE
DCOM- 20030708
LR  - 20190916
IS  - 1077-4114 (Print)
IS  - 1077-4114 (Linking)
VI  - 25
IP  - 6
DP  - 2003 Jun
TI  - The epidermal growth factor receptor HER2 is not a major therapeutic target in 
      Ewing sarcoma.
PG  - 459-66
AB  - BACKGROUND: Although chimeric EWS gene and Ets gene fusions are pathognomonic of 
      Ewing sarcoma (ES) and primitive neuroectodermal tumors (PNET), the molecular 
      pathogenesis of these pediatric malignancies is poorly understood. Recently, the 
      human epidermal growth factor (HER)-2 receptor, which plays an important role in 
      the biology of certain epithelial cancers, has been implicated in ES tumor cell 
      line growth and chemosensitivity. MATERIALS: To investigate whether HER2 might be 
      a rational target for ES/PNET therapy, five ES cell lines and 13 archival primary 
      ES/PNET samples were examined by immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH) for evidence of HER2 overexpression. RESULTS: Although 
      several ES cell lines demonstrated modest constitutive HER2 expression by 
      immunoblot, none of the ES cell lines or primary tumor samples showed evidence of 
      HER2 overexpression by IHC or HER2 gene amplification by FISH. Moreover, 
      treatment of human ES cell lines with the HER2-targeted agent trastuzumab 
      (Herceptin) had little effect on cell survival, proliferation, or growth in 
      semi-solid medium. CONCLUSIONS: These results suggest that HER2 is not a 
      biologically or therapeutically important pathway in ES/PNET.
FAU - Ye, Dan
AU  - Ye D
AD  - Division of Hematology/Oncology and Simmons Cancer Center, University of Texas 
      Southwestern Medical Center, Dallas, Texas 75390-8593, USA.
FAU - Maitra, Anirban
AU  - Maitra A
FAU - Timmons, Charles F
AU  - Timmons CF
FAU - Leavey, Patrick J
AU  - Leavey PJ
FAU - Ashfaq, Raheela
AU  - Ashfaq R
FAU - Ilaria, Robert L Jr
AU  - Ilaria RL Jr
LA  - eng
GR  - HL03310/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Blotting, Western
MH  - Bone Neoplasms/drug therapy/*metabolism
MH  - Cell Survival
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*metabolism
MH  - Sarcoma, Ewing/drug therapy/*metabolism
MH  - Trastuzumab
MH  - Tumor Cells, Cultured
EDAT- 2003/06/10 05:00
MHDA- 2003/07/09 05:00
CRDT- 2003/06/10 05:00
PHST- 2003/06/10 05:00 [pubmed]
PHST- 2003/07/09 05:00 [medline]
PHST- 2003/06/10 05:00 [entrez]
AID - 10.1097/00043426-200306000-00007 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2003 Jun;25(6):459-66. doi: 
      10.1097/00043426-200306000-00007.